Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fast Approval Of Pandemic Flu Vaccines With Adjuvants Could Face Regulatory Barrier

This article was originally published in The Pink Sheet Daily

Executive Summary

Current FDA regulations may pose a barrier to fast approval of pandemic influenza vaccines that include an adjuvant for novel strains, HHS' National Vaccine Program Office says.

You may also be interested in...



Avian Flu Collaborations: Aventis, Chiron To Produce Vaccine For NIH Clinical Trials

Each company will manufacture 8,000 doses of the avian strain under contracts with the National Institutes of Health. Aventis will perform stability testing to see if its vaccine is suitable for stockpiling.

Influenza Pandemics May Require Multiple Vaccine Dosing For Adults

CBER Office of Vaccine Research & Review Acting Director William Egan says that naive adults are similar to children when it comes to vaccine dosing. NIH is conducting studies on strains to which the population is naive.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel